1-1 of 1
Zheng Yuan, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Zonder A Jeffrey, MD, Vishal Kukreti, MD FRCPC, Stefan O Schoenland, MD, Arnaud Jaccard, MD, Angela Dispenzieri, MD, Adam D. Cohen, MD, Deborah Berg, RN, MSN, Zheng Yuan, PhD, Ai-Min Hui, MD PhD, Palladini Giovanni, MD PhD, Raymond L. Comenzo, MD
Journal: Blood
Blood (2014) 124 (21): 3450.
https://doi.org/10.1182/blood.V124.21.3450.3450
Published: 2014